Strategic asset sale The company historically divested assets to larger players (sale of commercial assets to CooperSurgical). This indicates a potential partnership or acquisition angle with manufacturers and distributors of fertility genetics products seeking to consolidate offerings.

Clinical testing focus Specialization in carrier screening and genetics with a strong emphasis on genetic counseling suggests opportunities to partner with clinics and fertility centers that require end-to-end genomic testing combined with counseling services.

Moderate scale, global reach Current employee count and revenue range imply a boutique yet globally served operation. This points to scalable collaboration opportunities with larger healthcare providers, CROs, or insurers seeking specialized genomics capabilities without a huge integration burden.

Data-driven genomics Emphasis on big data and personalized genomics opens doors for collaborations with data analytics firms, biopharma, and research networks aiming to augment product pipelines with fertility-related or broader genetic insights.

Financially opportunistic With modest revenue and substantial funding, there is potential for joint development, co-funded studies, or licensing deals to extend product lines, expand geographic coverage, or accelerate market entry through partners with larger distribution networks.